Pre-Approval Inspections and Alternative Approaches to Facility Assessment (4/15) Global Quality

Mahesh Ramanadham and Derek Smith, CDER Office of Pharmaceutical Quality, note that during the COVID-19 public health emergency, FDA is utilizing all available tools and sources of information to support regulatory decisions on applications that include sites impacted by FDA’s ability to inspect due to COVID-19. They discuss OPQ's approach to manufacturing facility assessment.
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cd...
CDER SBIA 2020 Playlist: • 2020 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cd...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.go...
Email: [e-mail]
Phone: [phone] I [phone]